Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
In the key Phase 3 ATTAIN-1 trial published in the New England Journal of Medicine in 2025, once-daily orforglipron 36 mg produced mean body weight reductions of 11.2% at 72 weeks in adults with obesity, with nearly 55% of participants achieving at least 10% weight loss and 36% achieving 15% or more
This foundational discovery established GHK as a biological signal of youth whose progressive decline with age tracks closely with decreased healing capacity and visible tissue deterioration
Gerald KB
The steady state
Accordingly, pharmacological strategies that lower KYNA levels can enhance cognition, but sustained reductions in KYNA may increase vulnerability to mood disturbances by removing its inhibitory influence on excitatory signalling
US$ 22.53
US$ 21.36
US$ 20.05
US$ 28.12
US$ 29.38
